Catherine Moukheibir joined our board of directors in April 2019. Ms. Moukheibir currently serves as chief executive officer, as well as chairman of the board of directors, of MedDay Pharmaceuticals, or MedDay. Prior to that, Ms. Moukheibir served as the senior advisor for finance and a member of the executive board of directors at Innate Pharma SA from March 2011 to December 2016, and as the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired. Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007. In addition to her service on the board of directors of MedDay, Ms. Moukheibir also serves on the board of directors of Orphazyme A/S, Genkyotex SA, and Kymab Group Limited. She also held past directorships on the boards of directors of Ablynx NV, Cerenis Therapeutics SA and Creabilis S.A. Ms. Moukheibir has an M.A. in economics and an M.B.A. from Yale University.